Prothena

Bristol Myers Squibb booth at AACR 2026
Biotech

BMS walks away from $80M neurodegeneration bet after phase 1

The Prothena-partnered program, dubbed BMS-986495, was being developed as a potential treatment for neurodegenerative diseases.
Marissa Russo Oct 29, 2026 10:53am
Parachute over La Jolla California

Metsera sale architect swings to Structure—Chutes & Ladders

Apr 17, 2026 10:10am
positive negative up down good bad mixed

Novo Nordisk shares mixed data behind pivotal heart disease push

Nov 11, 2025 8:32am
human brain abstract art

Prothena Alzheimer's trial hit by ARIA showstopper

Aug 28, 2025 6:48am
A series of dice with a bag on them illustrating cost cuts

Prothena lays off 63% in fallout from phase 3 amyloidosis fail

Jun 20, 2025 2:23am
balloon missed target pop arrows miss failure

Prothena reburies drug after 2nd swing at rare disease misses

May 27, 2025 3:33am